Santen Pharmaceutical Co., Ltd. (SNPHY)

Market Cap	3.78B
Revenue (ttm)	2.00B
Net Income (ttm)	242.05M
Shares Out	n/a
EPS (ttm)	0.69
PE Ratio	15.60
Forward PE	n/a
Dividend	19.13 (173.43%)
Ex-Dividend Date	Sep 29, 2025

Volume	1,461
Average Volume	3,933
Open	11.01
Previous Close	11.24
Day's Range	11.01 - 11.03
52-Week Range	8.65 - 13.00
Beta	0.22
RSI	46.02
Earnings Date	Aug 7, 2025

About FARO Technologies

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2α derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertension; and ciclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis, as well as latanoprost, an ophthalmic emulsion of a prosta...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1890
• Employees: 3,849
• Stock Exchange: OTCMKTS
• Ticker Symbol: SNPHY

Financial Performance

In 2024, Santen Pharmaceutical's revenue was 300.00 billion, a decrease of -0.65% compared to the previous year's 301.97 billion. Earnings were 36.25 billion, an increase of 36.09%.